AlphAIalphai — Financial news for AI agents
gurufocus.comSEP 22 min read$SMMT

Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res

Summit Therapeutics (SMMT) shares rose 3% after its partner Akeso reported positive Phase III trial results for ivonescimab, showing a survival advantage over pembrolizumab in lung cancer. The company has a high P/S ratio of 369.4x, reflecting growth expectations. Insiders bought $126.6M in shares, but the company remains unprofitable.

Original reporting
gurufocus.com
Published Sep 2, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 3:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
9/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The Phase III HARMONi‑2 trial outcome is a material catalyst that could drive near‑term price movement and long‑term valuation.

02

Market read

First‑report of pivotal trial data; likely to influence biotech sector sentiment and SMMT's stock trajectory.

03

What to watch

Insider buying of $126.6 M suggests confidence, but trial success does not guarantee regulatory approval or market adoption.

Relevance 9/10Novelty 9/10Timing: after‑hours Sep 2 2026

Background

Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech focused on antibiotics and oncology, partnering with Akeso for ivonescimab.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase III trial, driving a ~3% after‑hours price rise.

Expected impact

Potential upside of 10‑15% if data leads to FDA filing and market optimism.

Evidence & confidence

Biotech stocks typically rally on pivotal trial success; the magnitude of survival benefit is material and the market has already reacted positively.

Market effects

Sector

Strengthens the oncology biotech sector and may lift peers developing PD‑L1 inhibitors.

Regional

Positive for US biotech listings; limited direct impact on other regions.

Global

Adds to global confidence in immuno‑oncology pipelines.

Counterpoint

What could challenge this read

High valuation (P/S ~369x) and cash‑flow negativity could limit upside; investors may wait for commercialization data.

Key entities

  • company
    Summit Therapeutics Inc.

    US‑listed biotech developing ivonescimab.

  • partner
    Akeso

    Conducted the Phase III HARMONi‑2 trial.

Read at source← All news

Related articles

SEP 3
$SMMTMedAI 8/10

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in

Akeso Inc. reported positive overall survival results from the HARMONi-2 study, showing ivonescimab monotherapy outperformed pembrolizumab in PD-L1-positive advanced NSCLC. Summit Therapeutics (SMMT) noted the findings, with ivonescimab approved in China and under investigation in other regions. The study's hazard ratio was 0.51 (p<0.0001). Summit is conducting further trials, including HARMONi-7 for PD-L1 high-expressing NSCLC.

biospace.com2 min
AUG 27
$SMMTHighAI 8/10

Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

Summit Therapeutics (SMMT) rose 8.5% after partner Akeso's Phase III trial showed ivonescimab plus chemotherapy improved survival rates in advanced biliary tract cancer. The drug's success adds to its lung cancer data and ongoing FDA review. Summit projects $897.3M revenue and $169.7M earnings by 2029, with analysts estimating potential $2.5B revenue by 2029.

simplywall.st2 min
AUG 27
$SMMTHighAI 9/10

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics (SMMT) shares rose 6.5% after partner Akeso reported positive phase III study results for ivonescimab in biliary tract cancer, showing superiority over AstraZeneca's (AZN) Imfinzi. The study met primary and secondary endpoints, including overall survival. Summit holds exclusive licensing rights for ivonescimab in multiple regions, excluding China. Year-to-date, SMMT shares are down 18.6% against industry growth of 3.2%.

finance.yahoo.com2 min
AUG 26
$SMMTHighAI 8/10

Summit Therapeutics Stock Rises 8%

Summit Therapeutics (SMMT) shares rose 7.78% to $14.40 Wednesday, possibly due to partner Akeso's positive Phase III trial results for ivonescimab in advanced biliary tract cancer. The stock traded between $14.11 and $15.10, with volume at 7.52 million shares. Akeso reported statistically significant overall survival benefits in the HARMONi-GI1 study.

rttnews.com1 min
AUG 26
$SMMTHighAI 9/10

Summit Therapeutics Shares Surge on Positive Phase III Data From Chinese Partner Akeso

Summit Therapeutics (SMMT) shares rose 8% to $14.40 after partner Akeso reported positive Phase III trial results for ivonescimab in advanced biliary tract cancer, meeting primary and secondary endpoints. The drug, a bispecific antibody, is key to Summit's pipeline, with an FDA decision pending for NSCLC. Investors consider potential and risks, including cash burn and recent stock offering.

asktraders.com2 min